Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/IIa Clinical Study to Evaluate the Tolerability, Safety and Preliminary Efficacy of T3011 in Subjects With Advanced Melanoma

NCT06214156 is registered in ClinicalTrials.gov with Shanghai Pharmaceuticals Holding Co., Ltd as lead sponsor.

NCT NCT06214156
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06214156 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/IIa Clinical Study to Evaluate the Tolerability, Safety and Preliminary Efficacy of T3011 in Subjects With Advanced Melanoma
Lead sponsor
Shanghai Pharmaceuticals Holding Co., Ltd
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 26, 2024
Completion date
September 30, 2026
Enrollment
42 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

advanced melanoma